Cargando…

Positive pleiotropic effects of HMG-CoA reductase inhibitor on vitiligo

BACKGROUND: HMG-CoA reductase inhibitors (statins) are commonly used in medicine to control blood lipid disorder. Large clinical trials have demonstrated that statins greatly reduces cardiovascular-related morbidity and mortality in patients with and without coronary artery disease. Also, the use of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Noël, Martin, Gagné, Claude, Bergeron, Jean, Jobin, Jean, Poirier, Paul
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2004
Materias:	Short Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC425594/ https://www.ncbi.nlm.nih.gov/pubmed/15134579 http://dx.doi.org/10.1186/1476-511X-3-7

Ejemplares similares

Pleiotropic effects of the HMG-CoA reductase inhibitors
por: Mihos, Christos G, et al.
Publicado: (2011)

Predictive Modeling of HMG-CoA Reductase Inhibitory Activity and Design of New HMG-CoA Reductase Inhibitors
por: Samizo, Shigeyoshi, et al.
Publicado: (2023)

Chronic Onset Form of Anti-HMG-CoA Reductase Myopathy
por: Lorenzo-Villalba, Noel, et al.
Publicado: (2021)

Role of HMG-CoA reductase inhibitors with curative radiotherapy in men with prostate cancer
por: Solanki, Abhishek A, et al.
Publicado: (2011)

Targeting Enterococcus faecalis HMG-CoA reductase with a non-statin inhibitor
por: Bose, Sucharita, et al.
Publicado: (2023)

The role of HMG-CoA reductase inhibition in endothelial dysfunction and inflammation
por: Gelosa, Paolo, et al.
Publicado: (2007)

Transcription of the three HMG-CoA reductase genes of Mucor circinelloides
por: Nagy, Gábor, et al.
Publicado: (2014)

Functional Implications of HMG-CoA Reductase Inhibition on Glucose Metabolism
por: Han, Ki Hoon
Publicado: (2018)

Eupatilin Alleviates Hyperlipidemia in Mice by Inhibiting HMG-CoA Reductase
por: Kim, Kyung-Joo, et al.
Publicado: (2023)

HMG-CoA reductase promotes protein prenylation and therefore is indispensible for T-cell survival
por: Lacher, Sonja M, et al.
Publicado: (2017)

HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome
por: Bengtsson, Erik, et al.
Publicado: (2014)

Chronic Anti-HMG-CoA Reductase Positive Necrotizing Myositis With Remote Exposure to Statins
por: Salar, Tooba, et al.
Publicado: (2023)

HMG CoA reductase inhibitors (statins) to treat Epstein–Barr virus-driven lymphoma
por: Cohen, J I
Publicado: (2005)

Association between Use of HMG CoA Reductase Inhibitors and Mortality in HIV-Infected Patients
por: Moore, Richard D., et al.
Publicado: (2011)

Direct free radical scavenging effects of water-soluble HMG-CoA reductase inhibitors
por: Umeda, Ryohei, et al.
Publicado: (2019)

Development of Clinical Data Mart of HMG-CoA Reductase Inhibitor for Varied Clinical Research
por: Kim, Hun-Sung, et al.
Publicado: (2017)

Use of HMG-CoA Reductase Inhibitors in the HIV Population: Implications for Individualized Treatment Selection
por: Advani, Ashish, et al.
Publicado: (2014)

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
por: Palmer, Suetonia C., et al.
Publicado: (2015)

HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis
por: Palmer, Suetonia C., et al.
Publicado: (2014)

Are Point Mutations in HMG-CoA Reductases (Hmg1 and Hmg2) a Step towards Azole Resistance in Aspergillus fumigatus?
por: Gonzalez-Jimenez, Irene, et al.
Publicado: (2021)

Exploration of natural product ingredients as inhibitors of human HMG-CoA reductase through structure-based virtual screening
por: Lin, Shih-Hung, et al.
Publicado: (2015)

The 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductases
por: Friesen, Jon A, et al.
Publicado: (2004)

Metabolomic Profiling of Statin Use and Genetic Inhibition of HMG-CoA Reductase
por: Würtz, Peter, et al.
Publicado: (2016)

The prenyltransferase UBIAD1 is the target of geranylgeraniol in degradation of HMG CoA reductase
por: Schumacher, Marc M, et al.
Publicado: (2015)

Cholesterol, C-Reactive Protein, and Periodontitis: HMG-CoA-Reductase Inhibitors (Statins) as Effect Modifiers
por: Meisel, Peter, et al.
Publicado: (2011)

Benefit–risk assessment of HMG-CoA reductase inhibitors (statins): a discrete choice experiment
por: Wanishayakorn, Tanatape, et al.
Publicado: (2016)

Pilot Algorithm Designed to Help Early Detection of HMG-CoA Reductase Inhibitor-Induced Hepatotoxicity
por: Hong, Joo Young, et al.
Publicado: (2017)

Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by HMG-CoA reductase inhibitor
por: Chen, K.-H., et al.
Publicado: (2011)

Potential natural inhibitors of xanthine oxidase and HMG-CoA reductase in cholesterol regulation: in silico analysis
por: Marahatha, Rishab, et al.
Publicado: (2021)

Statins: HMG-CoA Reductase Inhibitors as Potential Anticancer Agents against Malignant Neoplasms in Women
por: Markowska, Anna, et al.
Publicado: (2020)

HMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of Myocarditis by Inhibiting Metalloproteinases Activation
por: Skrzypiec-Spring, Monika, et al.
Publicado: (2021)

Carbohydrate restriction and dietary cholesterol modulate the expression of HMG-CoA reductase and the LDL receptor in mononuclear cells from adult men
por: Mutungi, Gisella, et al.
Publicado: (2007)

The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in renal disease
por: Gomez, Sabas I, et al.
Publicado: (2014)

Degradation of HMG-CoA reductase-induced membranes in the fission yeast, Schizosaccharomyces pombe
Publicado: (1995)

Lepidopteran HMG-CoA reductase is a potential selective target for pest control
por: Li, Yuan-mei, et al.
Publicado: (2017)

An Atomic-Level Perspective of HMG-CoA-Reductase: The Target Enzyme to Treat Hypercholesterolemia
por: Gesto, Diana S., et al.
Publicado: (2020)

Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
por: Kettunen, Johannes, et al.
Publicado: (2019)

Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity
por: Ludolph, Barbara, et al.
Publicado: (2007)

The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer
por: Stine, Jessica E., et al.
Publicado: (2015)

HMG-CoA Reductase Inhibitor Statins Activate the Transcriptional Activity of p53 by Regulating the Expression of TAZ
por: Miyajima, Chiharu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_arvi6s39l145joo6gpemfsj178